Skip to content
You can now search across every topic, entity and event.What's new
Timeline

Cytospire Therapeutics

London oncology biotech; first-in-class T cell engager drug for solid tumours; £61m Series A May 2026.

4 of 4 entries (4 events, 0 interactions)

Filters
#7 2 Jun
#4 5 May

Closed oversubscribed £61m Series A to advance CYT X300 pan-gamma delta T cell engager toward clinical trials

UK Startups and Innovation: Cytospire's £61m oncology Series A oversubscribed